|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Absolute bioavailability and phannacokinetics of valsartan, an angiotensin Ⅱ receptor antago- nist, in man 显示文摘 | FLESCH G MULLER P LLOYD P | 1997 | Eur J Clin Pharmacol1997，52，： | 1 |
| 2 | Improved determination of the bisphos- phonate pamidronate disodium in plasma and urine by pre -column de- rivitization with fluorescamine, high performance liquid chromatography and fluorescence detection显示文摘 | Flesch G Tominaga N Degen P | 1991 | J Chromatogr B1991，568，1： | 1 |
| 3 | Pharmacokinetics, disposition and biotransformation oW'C]-radiolabelied valsartan in healthy male vol?unteers aftera single oral dose显示文摘 | Waldmeier F Flesch G Muller P | 1997 | Xenobiotica1997，27，1： | 1 |
| 4 | Pharmacokinetics disposition and biotransformation of-radiolabelled valsartan in healthy male volunteer after a single oral dose显示文摘 | Waldmeier F Flesch G Muller P | 1997 | Xenobiotica1997，27，： | 1 |
| 5 | Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin Ⅱ receptor antagonist, in man显示文摘 | Flesch G MUller P Lloyd P | 1997 | Eur J Clin Pharmacol1997，52，2： | 1 |
| 6 | Clinical pharmacology and pharmacokinetics of oxcarbazepine显示文摘 | Lioyd P Flesch G Dieterle W | 1994 | Epilepsia1994，35，3： | 1 |
| 7 | Clinical pharmacology and pharma- cokinetics of oxcarbazepine显示文摘 | Lloyd P Flesch G Dieterle W | 1994 | Epilepsia1994，35，： | 1 |
| 8 | Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by pre-column derivatization with fluorescamine, highperfor- mance liquid chromatography and fluorescence detection显示文摘 | Flesch G Tominaga N Degen P | 1991 | J Chromatogr B1991，568，： | 1 |
| 9 | Role of G-proteins in altered β-adrenergic responsiveness in the failing and hypertrophied myocardium显示文摘 | Bohm M Flesch M Schnabel P | 1996 | Basic Res Cardiol1996，91，： | 1 |
| 10 | AVO classification of lithology and pore fluids constrained by rock physics depth trends显示文摘 | AVSETH P FLESCHE H WIJINGAARDEN A J | 2003 | The Leading Edge2003，22，： | 1 |
| 11 | Absolute bioavailability and pharmacokinetics of valsartan,an angiotensin Ⅱ receptor antagonist,in man显示文摘 | Flesch G Muller P Muller P | 1997 | Eur J Clin Pharmacol1997，52，： | 1 |
| 12 | Pharmacokinetics,disposition and biotransformation of-radiolabelled valsartan in healthy male volunteers after a single oral dose显示文摘 | Waldmeier F Flesch G Muller P | 1997 | Xenobiotica1997，27，： | 1 |
| 13 | Clinical pharmacology and pharmacokinetics of oxcarbazepine显示文摘 | Lloyd P Flesch G Dieterle W | 1994 | Epilepsia1994，35，3： | 1 |
| 14 | Absolute bioavailability and pharmacokinetics of valsartan,an angiotensin Ⅱ receptor antagonist,in man显示文摘 | Flesch G Müller P Lloyd P | 1997 | Eur J Clin Pharmacol1997，52，2： | 1 |
| 15 | Absolute bioavailability and pharmacokinet i cs of valsartan,an angiotensin Ⅱ receptor antagonist,in man显示文摘 | Muller P Lloyd P | 1997 | Eur J Clin Pha rmacol1997，52，2： | 1 |
| 16 | Absolute bioavailability and pharmacokineties of valsartan ,an anglotension Ⅱ receptor antagonist,in man显示文摘 | Flesch G Muller P Lloyd P | 1997 | Eur J Clin Pharmacol1997，52，2： | 1 |
| 17 | Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin 1I receptor ant-agonist, in man 显示文摘 | Flesch G Miiller P Lloyd P | 1997 | Eur J Clin Pharmacol1997，52，2： | 1 |
| 18 | Clinical pharmacology and pharmacokinetics of oxcarbazepine显示文摘 | Lloyd P Flesch G Dieterle W | 1994 | Epilepsia1994，35，3： | 1 |
| 19 | Absolute bioavailability and pharmacokinetics of valsartan, and angiotensin II receptor antagonist, in man 显示文摘 | FLESCH G MULLER P LLOYD P | 1997 | Eur J Clin Pharmacol1997，52，2： | 1 |
| 20 | β-Adrenergic signaltransduction in the failing and hypertrophied myocardium显示文摘 | Bohm M Flesch M Schnabel P | 1997 | J Mol Med1997，75，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员